YSOPIA Bioscience’s management team is deeply inspired by companies that have been able to transform scientific discoveries into innovative pharmaceutical products thanks to their strong vision and successful strategy.

LNC - Georges Dr.  Rawadi, (PhD, MSc), CEO
Passionate about innovation

Dr. Georges Rawadi, CEO (PhD, MSc)

A former researcher at the Institut Pasteur, Georges was Vice-President of Business Development & Intellectual Property and a member of the management team at Celyad.

He previously served in various business development roles at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis and led strategic alliance development consulting assignments.

He holds a PhD in Microbiology from Pierre and Marie Curie University (France) and a master’s degree in Management and Strategy in the Health Industry from ESSEC Business School.

LNC - Sandrine Dr. Sandrine Claus (PhD, MRSB), CSO
Beyond state of the art

Dr. Sandrine Claus, CSO (PhD, MRSB)

Sandrine joined YSOPIA Bioscience in 2017 as Chief Scientific Officer. She previously served as Associate Professor in Integrative Metabolism at the University of Reading’s department of Food and Nutritional Sciences.

Her research focused on host-gut microbial metabolic interactions in order to link gut microbial ecology to metabolic health.

A scientist at heart, Sandrine founded her own laboratory at the age of 27, after obtaining her PhD in Biochemistry at Imperial College London, where she started to study host-gut microbiota metabolic interactions.

LNC - Fabrice Fabrice Guez, co-founder & CFO
Putting people first

Fabrice Guez, CFO and co-founder 

An experienced CFO, Fabrice decided to switch gears after gaining extensive experience as a financial auditor, getting involved in operations at a number of pharmaceutical SMEs, where he successfully headed up change management processes, thanks to his flexibility and excellent people skills.

Fabrice co-founded YSOPIA Bioscience in 2010, firmly convinced by its innovative approach and keen to take on an entrepreneurial challenge.

LNC - Frédéric Frédéric Elustondo, Senior Director of Operations
Execute the right project

Frédéric Elustondo, Director of Operations

Experienced Manager, Frederic’s expertise focuses on project management and innovation in the different positions he held in the hospital & health care industry. He managed numerous projects primarily on Oncology from early proof of concept to clinical development at Cancer Research Technology (CRUK DL), RedX Pharma or Institut Bergonié.

Frederic is a trained organic chemist and hold a Ph.D. from the Nottingham University after initial training at the University of Bordeaux.

Our values

Board of

Real “sparring partner” for YSOPIA Bioscience’s management team, our board is gathering Biotech & Life Sciences specialists.

LNC - Jean-Gérard Galvez, Chairman

Jean-Gérard Galvez, president YSOPIA Bioscience

Jean-Gérard brings 35 years of international experience in Operations, Management, M&A’s and IPO’s. He serves on several Boards of private and publically traded companies in the medical and software industries. 

more +

Based in California from 1995 to 2008, Jean-Gerard was Chairman and CEO of ActivCard, a 2B$ market capitalization – Nasdaq listed company.

In his earlier professional experiences Jean-Gerard worked as Vice President of several large IT companies (Control Data Corporation, DuPont Corporation).

He graduated from the Stanford Executive Program, holds a Chemical Engineering degree and a Master’s degree in Business Administration..

LNC - Isabelle  de Crémoux, president & CEO Seventure Partners

Isabelle de Crémoux, president & CEO Seventure Partners

Isabelle brings 25 years of international experience in life sciences business development and finance. She started her career in ’91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development.

more +

Since ’98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the lifesciences department.

Isabelle leads the lifesciences team and makes direct investments, mainly in France and Scandinvia with a focus on biotech, nutrition, personalized medicine and especially microbiome. Isabelle’s trackrecord includes Santaris (solde to Roche for $450 millions in august 2014), argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience.

LNC - Mathieu  Simon (MD)

Mathieu Simon (MD)

Mathieu is today Senior Advisor at Messier Maris & Associés an advisory M&A firm located in Paris, New York and London. In addition to this role, Mathieu Simon is a Venture partner at B/B Pureos Bioventures (Bellevue Venture Capital) in Zurich, CH.

more +

Dr Simon is also an independent director at the Board of Vaximm AG (CH ), and member of Affimed supervisory board (AFMD NASDAQ ) and has been Chairman of the Board of Cellartis AB a pioneer in regenerative medicine in Sweden until 2014 before its acquisition by Takara Bio.

Mathieu SIMON, MD, has served also as Executive Vice-President, Chief Operating Officer of Cellectis since 2012 and as Member of the Board of Cellectis since 2014. Prior to this function Mathieu Simon was CEO of Cellectis Therapeutic and CEO of Ectycell from 2012 to 2014. Mathieu Simon as head of Cellectis Therapeutics with Andrew Scharenberg, MD (Seattle Children’s hospital) serving as CSO have been very instrumental in the development of Cellectis first in class allogenic CAR T cells targeting haematological malignancies now today in clinical development in the USA.

Prior to joining Cellectis, Dr SIMON was Managing Director, Head of Global Pharma at Pierre Fabre SA, the third largest French Pharma Company. Prior to this role, Dr Simon has worked 18 years at Wyeth Pharmaceuticals where he had several general management and regional roles in the EU region (10 years as President of Wyeth Italy) as swell as senior corporate functionsas Senior Vice President Head of Wyeth Global Marketing and Medical Affairs in Philadelphia, USA.

Dr Mathieu Simon is also advisor of the EU Commission (Horizon 2020 Programme)

LNC - Catherine  Combot-Pletan, Pharm D

Catherine Combot-Pletan (Pharm D)

Catherine has more than 20 years of experience in Start-up, Biotech, Pharma, CRO and Consulting mainly in strategy and project management for R&D programs of innovative biologic drugs.

more +

Her career started by Clinical Research and she has been Head of the Clinical Department of Chiltern International for many years, with the responsibility of all clinical trials in several countries.

Then she moved to the full drug development and has acquired an expertise in Global Operations, CMC, Regulatory & Translational project management of NBE’s early development with a global vision from Research all the way to Market Launch.

She successfully led products up until phase II POC through several positions notably as Strategic Project Director on blood factors and Mabs Programs in LFB Biotechnologies then as Head of Projects Development in Gamamabs Pharma where she had the responsibility of the global operations and has contributed to funds raising.

Since 2016, she is the President and Founder of ULTRace Development Partner whereby she advises biotechs and start-ups by creating value through strategic support, operations development and project management. She is also member of the management team for some of them.

LNC - Georges Dr.  Rawadi (PhD, MSc)

Dr. Georges Rawadi (PhD, MSc)

A former researcher at the Institut Pasteur, Georges was Vice-President of Business Development & Intellectual Property and a member of the management team at Celyad.

more +

He previously served in various business development roles at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis and led strategic alliance development consulting assignments.

He holds a PhD in Microbiology from Pierre and Marie Curie University (France) and a master’s degree in Management and Strategy in the Health Industry from ESSEC Business School.

LNC - Virginie  Lleu, managing director L3S Partnership

Virginie Lleu, managing director L3S Partnership

Holding a Supplementary Specialised Studies Diploma (DESS) in Clinical Psychopathology, and bilingual in English, she started her professional career by gaining clinical experience in hospitals as a neuropsychologist.

more +

In 1992, Virginie Lleu joined the pharmaceutical company Jouveinal to work in its Human Resources Directorate. She then moved as a consultant to a recruitment agency specialised in the healthcare field, GSA, subsequently joining Pact & Partners International as Senior Consultant responsible for the Health and Biotechnologies sector.

As from 2000, Virginie pursued her work as a recruitment consultant with Executive Search International entities such as Korn Ferry International and Spencer Stuart, where she contributed to developing the Health and Biotechnologies Department.

After accomplishing a large number of missions in a variety of functions (general management, R&D, marketing/sales, manufacturing, business development, HR, finance, etc.), in 2003 Virginie founded L2S (Life Science Search), a recruitment consultancy based on direct contact and dedicated specifically to healthcare. L2S soon became a market leader in the life sciences in France and Europe. Five years after it was set up, in 2008, L2S was sold to Whitehead Mann, and Virginie Lleu became Senior Client Partner Life Sciences for Europe, supervising a team of some fifteen people.Drawing on her wide-ranging and significant experience and expertise developed at L2S, in October 2010 Virginie Lleu created the L3S Partnership, the aim being to become one of the leading executive search companies for the life sciences in Europe.

Scientific Advisory Board

Our Scientific Advisory Board brings together international experts with expertise in gut microbiome and clinical development

LNC - Jean-Pierre Dr. Lehner, SAB Chairman (MD)

Dr. Jean-Pierre Lehner, SAB Chairman (MD)

Previously, Dr. Lehner has held several executive positions within large pharmaceutical companies, including Sanofi, Roussel, and Roussel-UCLAF in France.

more +

He was Sanofi’s Chief Medical Officer from 2005 until 2012. Currently, Dr. Lehner is a Board Member for several life sciences companies to which he provides his expertise in new health products clinical development and his knowledge of the pharmaceutical industry. Dr. Lehner earned his medical degree from the University of Paris School of Medicine.

LNC - Joël Doré, Dr (PhD)

Dr. Joël Doré (PhD)

Joël is the Director of Research at the Micalis Institute and is the National Institute of Agricultural Research (INRA) Scientific Director of the MetaGenoPolis unit (Jouy-en-Josas, France) since 2012.

more +

Dr. Doré joined INRA in 1983 where he has been conducting research on intestinal microbiome for over 35 years. He was appointed as one of five deputy heads of the Micalis Institute (microbiology of food for health) between 2010 and 2014.

Dr. Doré serves as chairman of the European Society of Neurogastroenterology and Motility’s online scientific information platform, Gut Microbiota For Health. Dr. Doré is the author of more than 200 scientific publications related to intestinal microbiome.
He received his doctorate degree from the University of Illinois at Urbana-Champaign. 

LNC - Karine Clément , Prof. (MD, Tenured Professor of Nutrition (PU-PH)

Prof. Karine Clément (MD, Tenured Professor of Nutrition (PU-PH)

Karine is Head of the NutriOmic unit (INSERM/University of the Sorbonne), nutrition department in the Pitié-Salpêtrière hospital, Paris. Her research interests include physiopathological mechanisms of obesity in humans in its various states of progression and co-morbidities.

more +

Previously, she has held several leadership positions at prestigious scientific units, such as the ICAN university hospital unit (2011 – 2016) and Inserm’s “AVENIR” team, a program allowing researchers to set up and lead a team within an existing research structure once they have successfully defended their scientific thesis, at the Hôtel-Dieu hospital (2002 – 2006).

Prof. Clément currently serves as the Chief Scientific Advisor to the World Obesity Foundation and sits on the scientific advisory board of numerous well-known foundations and international organizations.
In addition to that, she provides the benefit of her expert scientific knowledge to academic institutions such as the Novo Nordisk Foundation Center for Basic Metabolic Research in Copenhagen. She has published over 300 scientific papers in highly renowned peer-reviewed journals and submitted 8 patents.

LNC - Eric  Ravussin, Dr. (PhD)

Dr. Eric Ravussin (PhD)

Eric is a Boyd Professor at the University of Louisiana, the Director of the Nutrition Obesity Research Center and the Douglas L. Gordon Chair in Diabetes and Metabolism, Associate Executive Director for Clinical Science at the Pennington Biomedical Research Center, Baton-Rouge.

more +

Dr. Ravussin is a world expert in the conduct of translational research in obesity and type 2 diabetes.
He has served as the Chief Obesity Research Officer of Eli Lilly,  in Indianapolis, and worked for 14 years at the Diabetes and Digestive and Renal Disease branch of the National Institue of Diabetes and Digestive and Kidney Diseases in Phoenix, where he played a key role in landmark studies on the causes of obesity and type 2 diabetes in Pima Indians. Since 2012, Dr. Ravussin is Editor in Chief of the journal Obesity.

He has been an active member of The Obesity Society, serving on the Council, the program committee and as a former President of the Society from 2006-2008. He has published more than 450 peer-reviewed papers on obesity, type 2 diabetes and aging. Dr. Ravussin obtained a doctorate degree in Human Physiology from the University of Lausanne, Switzerland. 


LNC - James Kinross, Dr (MD)

Dr. James Kinross (MD)

James serves as a faculty of Medicine, Department of Surgery & Cancer and Clinical Senior Lecturer in Colorectal Surgery at the Imperial College of London. Dr. James Kinross is also consulting colorectal surgeon at St. Mary’s Hospital, London.

more +

Dr. James Kinross is Clinical Senior Lecturer in Colorectal Surgery at Imperial College London’s Faculty of Medicine. He is also a consultant  colorectal surgeon at St. Mary’s Hospital, London. His clinical interests include minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He is currently funded by the Bowel and Cancer Research charity and the NIHR Imperial Biomedical Research Centre.

He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. Previously, he was an NIH Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery. Currently, he is a visiting Professor at the Royal College of Surgeons of Ireland. He was trained in northwest London.


Prof. Nicola Segata (PhD)

Nicola is Associate Professor at the CIBIO Department at the University of Trento (Italy). His lab comprises more than 20 researchers and employs experimental metagenomic tools and novel computational approaches to study the diversity of the microbiome across conditions and populations and its role in human diseases and infections.

more +

Nicola Segata, Ph.D., is Associate Professor at the CIBIO Department at the University of Trento (Italy). His lab (http://segatalab.cibio.unitn.it/) comprises more than 20 researchers and employs experimental metagenomic tools and novel computational approaches to study the diversity of the microbiome across conditions and populations and its role in human diseases and infections. The projects in the lab bring together computer scientists, microbiologists, statisticians, and clinicians and are generally focused on profiling microbiomes with strain-level resolution and on the meta-analysis of very large sets of metagenomes with novel computational tools. His work is supported by the European Research Council and by several other European agencies.

Microbiome & us
Jul 6, 2021
YSOPIA Successfully Completes Phase 1 Clinical Study of Xla1 Biotherapy for the Treatment of Obesity and Metabolic...
> more
Jun 1, 2021
90 seconds to learn more about YSOPIA Bioscience | [video width="1080" height="1080"...
> more
Press / Media
Jun 16, 2021
Forte de la découverte de Christensenella, une bactérie naturellement présente dans les microbiotes sains, la...
> more
May 24, 2021
Sur un marché mondial estimé à deux milliards de dollars d’ici à 2030, la filière du microbiome pharma veut...
> more
Jun 21, 2021
In this e-poster presented at the World Microbiome Forum taking place virtually from 20th to 24th June, you will figure...
> more
Jun 9, 2021
by Guillaume Déjean, Héloïse Tudela, Lisa Bruno, Déborah Kissi, Georges Rawadi and Sandrine P. Claus Access to...
> more
now on twitter
YSOPIA Bioscience

Discover how Christensenella bacteria expresses a specific Bile Salt Hydrolase, opening promising avenues to better… t.co/XayltxEqr7

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions